The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | Approaching R/R Hodgkin lymphoma in the era of frontline checkpoint inhibitors
Amanda Cashen, MD, Washington University School of Medicine, St. Louis, MO, shares that managing relapsed/refractory (R/R) Hodgkin lymphoma in 2025 is challenging due to the high likelihood of patients having received a checkpoint inhibitor in the frontline setting. She discusses her approach to managing these patients, including combining brentuximab with checkpoint inhibitors or chemotherapy. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I am challenged in the management of relapsed patients in 2025 because most of them will probably have seen nivolumab in the frontline setting, which really challenges my current paradigm of using nivolumab or pembrolizumab for relapsed patients. I think I’ll be using more brentuximab in the relapse setting moving forward as it becomes less likely that patients were treated with brentuximab in the front line so combinations of brentuximab with a checkpoint inhibitor like the BV-nivolumab regimen combinations of brentuximab with chemotherapy like BV-ICE or BV-gemcitabine those become more appealing options for patients who have already been treated with a checkpoint inhibitor...
I am challenged in the management of relapsed patients in 2025 because most of them will probably have seen nivolumab in the frontline setting, which really challenges my current paradigm of using nivolumab or pembrolizumab for relapsed patients. I think I’ll be using more brentuximab in the relapse setting moving forward as it becomes less likely that patients were treated with brentuximab in the front line so combinations of brentuximab with a checkpoint inhibitor like the BV-nivolumab regimen combinations of brentuximab with chemotherapy like BV-ICE or BV-gemcitabine those become more appealing options for patients who have already been treated with a checkpoint inhibitor.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
